Abstract 162P
Background
Hepatocellular carcinoma (HCC) after curative treatment has an estimated 5-year recurrence rate up to 70% [1]. Intrahepatic recurrence follows a bimodal pattern, with early recurrence occurring within 2 years and late recurrence occurring at 5 years [2]. It is unknown whether the bimodal recurrence pattern remains in the era of antivirals, which could reduce late recurrence. In this study, we provide an update of the characteristics of recurrence pattern.
Methods
Eligible patients who had received surgery or RFA for HCC from Oct 2000 to Jul 2017 were recruited at the Prince of Wales Hospital, Hong Kong. Patients’ and tumors’ characteristics were collected. Pattern of recurrence was classified by the occurrence of intrahepatic (local) recurrence or presence of distant metastasis (DM). Time-to-recurrence (TTR) and overall survival (OS) measure the time between the diagnosis of HCC to the time of first recurrence and death due to any cause respectively. Both TTR and OS were assessed using Kaplan-Meier Method. Prognostic factors for LR and DM were assessed using univariate and multivariate Cox Proportional Hazards Model.
Results
1082 patients were recruited. There were 908 (84%) males. 834 (77%) patients had HBV and 76 (7%) patients had HCV. 831 (77%) patients had BCLC stage 0/A and 243 (23%) patients had BCLC stage B/C HCC. 997 (92%) and 676 (63%) patients had Child-Pugh A and ALBI grade 1 liver function respectively. Median tumor size was 3.5cm. 834 (77%) patients had solitary HCC, and 99 (9%), 21 (2%) and 126 (12%) patients had 2, 3 and ≥3 HCCs respectively. 863 (80%) patients received surgery and 219 (20%) patients received RFA. The TTR for both LR and DM peaked at 9 to 12 months then dropped progressively. The bimodal recurrence pattern was not apparent. In patients who developed recurrence, median OS was longest in those with LR only at 64.8 months, versus shortest in those who developed DM first then LR at 13.3 months.
Conclusions
In the era of antivirals, the bimodal recurrence pattern is not observed with a marked reduction of late recurrence. The pattern of recurrence influences the prognosis: patients with LR have significantly better OS than DM. These findings are important for future research on adjuvant and salvage treatment for recurrent HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L.L. Chan: Other, Personal, Other, Travel Grant: Roche. K. Mok: Other, Personal, Other, Travel Grant: AstraZeneca, Eisai. S.L. Chan: Financial Interests, Personal, Advisory Board: Eisai, AstraZeneca, MSD, BMS, Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Eisai, Roche, Ipsen, BMS; Financial Interests, Personal, Research Grant: Eisai, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract